Scott Cleve brings an entire career dedicated to the mastery of global biopharma regulatory standards to his role as VP of regulatory operations and compliance at bluebird bio. Cleve joins the Business of Biotech podcast to discuss the regulatory trends shaping bluebird's pipeline of gene therapies for the treatment of serious, life-altering diseases. Listen now and subscribe so you never miss an episode.
Obtaining certain types of patent rights to antibodies has become increasingly challenging in the U.S. To comprehend this evolution, we must first take a careful look at what antibodies are, and then understand how they are claimed in a patent.
Biosimilars are here to stay, so it is essential that the different stakeholder groups (healthcare providers, patients) receive trustworthy and clear information about the principles and the value propositions.
It can be difficult to find industry-specific, easy-to-interpret, trustworthy market data. This ISR Reports e-book is chock full of free drug development and manufacturing facts, figures, and expert perspectives.